Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (935)	11/9/1997 2:41:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Dear Henry: This discussion is getting a bit too academic. Although I would like to, but I do have a matter requiring my attention which will last until Tuesday. I will do more post then. But for now, let me just say this. A replacement is like you had a car, somebody stole it and now your insurance gives you a car again. A "add on" is like your car windows somehow get too dirty to be washed clean to get enough sunlight and you can not replace your windows, now you put a sunroof in your car. Although the sunroof can get you enough sunlight, but nobody knows whether it will cause any leaking during a storm because this specific car was not designed to have a sunroof at the first place. Regarding to Resulin, the question is whether the receptor for prostaglandin J12 should be activated all the time in your body for the rest of your life (which is what diabetic patients have to do). Regards D.Right

To: Henry Niman who wrote (935)	11/17/1997 9:19:00 PM
From: D.Right	Read Replies (1) \| Respond to of 2173

Dear Henry: I do owe you one more discussion about the "replacement" and "add on"s. Pramlintide is a modified version of hormone amylin, and is a replacement treatment for amylin deficiency in diabetic patients. Rezulin is a modified version of prostaglandin, but it is an "add on" treatment for diabetic patients. The difference here is not whether they are modified or not, it is what is missing in patients compared to normal people. Normal people do have their amylin secreted all the time, and patients do not have it anymore. However, normal people do not have their PPAR gamma activated all the time (the receptor for Rezulin), and Rezulin "add on" that activation. For metabolism diseases like diabetes, the best treatment is "replacement" or "restoration" because the "add on" treatments sometimes add on something more than intended (liver problem for example). Unfortunately, in type II patients, what is missing is still not known, the decreased sensitivity to insulin is only a function on the surface (it is the phenotype, the genotype is unknown). What is missing maybe very complicated. That is why the response to Rezulin varies among the same type II patients grooup. At the meantime, I believe that pramlintide would only work in type II patients who do not have enough amylin to start with. Of course, all type I patients have amylin deficiency. My prediction is most type I patients will use amylin replacement. Many of type II patients will use amylin replacement on top of one form or the other of drugs like Rezulin. Rezulin will be wildly used even with its liver problems, but patients will watch out for it. I hope I answered your questions. Good luck with LGND D.Right